ORIGINAL ARTICLE   

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2021 September;65(3):271-5

DOI: 10.23736/S1824-4785.19.03157-1

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

[18F]fluorodeoxyglucose-positron emission tomography and glucose-transporter type 1 expression in untreated primary small bowel adenocarcinoma

Thomas HAUSER ^{1, 2}, Tina SCHALLER ³, Xiang LI ⁴, Thomas WIDMANN ⁵, Michael C. KREISSL ^{1, 6} ✉

¹ Department of Nuclear Medicine, Central Hospital Augsburg, Augsburg, Germany; ² Radiologie Augsburg-Friedberg, Augsburg, Germany; ³ Department of Pathology, Central Hospital of Augsburg, Augsburg, Germany; ⁴ Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, Austria; ⁵ Department of Oncology, Asklepiosklinik Triberg, Triberg, Germany; ⁶ Department of Radiology and Nuclear Medicine, University Hospital of Magdeburg, Magdeburg, Germany

BACKGROUND: Literature reporting [18F]fluorodexoyglucose positron emission tomography (FDG-PET) of small bowel adenocarcinoma, a rare tumor, is sparse. To assess FDG uptake in small bowel adenocarcinoma, we retrospectively analyzed a large, single-center database and determined the expression of glucose-transporter type 1 (GLUT-1).
METHODS: Screening of PET datasets in the database (N.=28,961 scans) for untreated histologically-confirmed primary small bowel adenocarcinoma revealed evaluable PET datasets for eight patients. Maximum and peak standardized uptake values (SUVmax and SUVpeak, respectively) were calculated via volume-of-interest (VOI) analysis. Additionally, GLUT-1 expression on tumor specimens was prospectively immunohistochemically assessed.
RESULTS: All primary tumors showed high FDG uptake: mean SUVmax was 9.5±2.6 (range: 5.0-13.0) and SUVpeak, 8.1±2.3 (range: 3.9-10.7). Corresponding biopsy specimens (N.=7) demonstrated high GLUT-1 expression.
CONCLUSIONS: Primary small bowel adenocarcinomas have a high GLUT-1 expression. Tumor lesions consistently demonstrated high FDG uptake pre-treatment, suggesting FDG-PET utility in staging and follow-up of these tumors.

KEY WORDS: Intestine, small; Adenocarcinoma; 4-fluoro-4-deoxyglucose; Glucose-transporter type 1